18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma

Loading...
Thumbnail Image
Date
2012
Authors
Shelly, M. J.
McDermott, S.
O'Connor, Owen J.
Blake, M. A.
Journal Title
Journal ISSN
Volume Title
Publisher
Hindawi Publishing Corporation
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for post treatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting.
Description
Keywords
Lymphoma , FDG-PET/CT , Fluorodeoxyglucose , Non-Hodgkin's lymphoma
Citation
Shelly, M. J., McDermott S., O'Connor O. J. and Blake M. A. (2012) '18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma', ISRN Hematology, 456706. http://dx.doi.org/10.5402/2012/456706